Literature DB >> 21122686

Complete Apo AI deficiency in an Iraqi Mandaean family: case studies and review of the literature.

Ahmad Al-Sarraf1, Khalid Al-Ghofaili, David R Sullivan, Kishor M Wasan, Robert Hegele, Jiri Frohlich.   

Abstract

Complete apo A1 deficiency is a rare genetic disorder that has been associated with premature atherosclerosis. We describe a family of Iraqi Mandaean background with complete apo A1 deficiency caused by a new nonsense mutation in the APOA1 gene. Interestingly, there were marked differences in the clinical presentation of the two homozygotes in this family. A 35-year-old woman presented with xanthelasmas and xanthomas but showed only minimal changes on cardiovascular examinations and no clinical symptoms. However, her 37-year-old brother was diagnosed with myocardial infarction at age 35. In addition, both the homozygotes had elevated C-reactive protein levels. The C-reactive protein levels increased three-fold during pregnancy, then decreased postpartum and further decreased with statin treatment. Cholesterol ester transfer protein mass was close to the upper reference range, whereas the activity was low, likely because of the lack of the substrate. Here, we characterize the phenotype and genotype of the first Middle Eastern family with apo A1 deficiency and compare and contrast the findings in the two homozygous siblings and review the previously reported cases of apo A1 deficiency. Crown
Copyright © 2010. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21122686     DOI: 10.1016/j.jacl.2010.05.001

Source DB:  PubMed          Journal:  J Clin Lipidol        ISSN: 1876-4789            Impact factor:   4.766


  4 in total

Review 1.  Genetics of HDL-C: a causal link to atherosclerosis?

Authors:  Julian C van Capelleveen; Andrea E Bochem; M Mahdi Motazacker; G Kees Hovingh; John J P Kastelein
Journal:  Curr Atheroscler Rep       Date:  2013-06       Impact factor: 5.113

2.  ApoA-I deficiency in mice is associated with redistribution of apoA-II and aggravated AApoAII amyloidosis.

Authors:  Yaoyong Wang; Jinko Sawashita; Jinze Qian; Beiru Zhang; Xiaoying Fu; Geng Tian; Lei Chen; Masayuki Mori; Keiichi Higuchi
Journal:  J Lipid Res       Date:  2011-05-26       Impact factor: 5.922

3.  Apolipoprotein AI deficiency inhibits serum opacity factor activity against plasma high density lipoprotein via a stabilization mechanism.

Authors:  Corina Rosales; Niket Patel; Baiba K Gillard; Dedipya Yelamanchili; Yaliu Yang; Harry S Courtney; Raul D Santos; Antonio M Gotto; Henry J Pownall
Journal:  Biochemistry       Date:  2015-04-02       Impact factor: 3.162

Review 4.  Diagnosis and treatment of high density lipoprotein deficiency.

Authors:  Ernst J Schaefer; Pimjai Anthanont; Margaret R Diffenderfer; Eliana Polisecki; Bela F Asztalos
Journal:  Prog Cardiovasc Dis       Date:  2016-08-24       Impact factor: 8.194

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.